4Biesert L. Virus validation studies of immunoglobulin preparations. Clin Exp Rheumatol, 1996,14( Suppl 15) : 47-52.
5Louie RE, Galloway CJ, Dumas ML, et al. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals, 1994, 22( 1 ) : 13-19.
6Kempf C, Jentsch P, Poirier B, et al. Virus inactivation during production of intravenous immunoglobulin. Transfusion, 1991,31 (5) :423-427.
7Bos OJ, Sunye DG, Nieuweboer CE, et al. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionatlon process. Biologicals, 1998,26 ( 4 ) :267-276.
9Boschetti N, Niederhauser I, Kempf C, et al. Different susceptibility of B19 virus and mice minute vires to low pH treatment. Transfusion ,2004,44( 7 ) : 1079-1086.
10Johnston A, Uren E, Johnstone D, et al. Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin Parametric and validation studies. Biologicals,2003,31 (3): 213-221.
